Compare Gogoro Inc (GGR) vs Organon & Co. Common Stock (OGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gogoro Inc vs Organon & Co. Common Stock — how do they compare? Gogoro Inc trades at $2.99 (market cap $65.04M), while Organon & Co. Common Stock trades at $13.58 (market cap $3.62B). The key difference: Organon & Co. Common Stock is far larger — about 55.7× Gogoro Inc's market cap, and Organon & Co. Common Stock pays a 0.58% dividend while Gogoro Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Gogoro Inc for 14 Days and Organon & Co. Common Stock for 0 Days on average.
| GGR | OGN | |
|---|---|---|
Market Cap | $65.04M | $3.62B |
Volume | 21,493 | 2,892,999 |
Sector | Consumer Cyclical | Health |
52-Week High | $4.66 | $13.81 |
52-Week Low | $2.20 | $5.70 |
Typical Hold Time | 14 Days | 0 Days |
Enterprise Value | $351.48M | $11.04B |
Dividend Yield | — | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GGR trades at $3.24, up 2.53% with a bullish technical signal despite negative profitability metrics. The company reported $281.48M revenue for 2025 but a net loss of $79.97M, though losses are projected to narrow in 2026. Recent developments include $61.8M in new equity investments and board appointments to strengthen governance. Technical indicators show bullish momentum with support at $3.00.
While technical momentum appears positive, fundamental challenges persist with negative margins and cash flow. The investment case hinges on Gogoro's ability to achieve profitability amid expansion costs. Analyst consensus remains cautious with 100% hold ratings, suggesting investors await clearer profitability signals before committing.
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Gogoro Inc
Gogoro is a global technology leader in battery-swapping ecosystems for electric two-wheelers. It provides smart, sustainable urban mobility solutions and manages an extensive network of battery stations.
Read more on GGR →About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →
